In a phase 2/3 study, the monovalent vaccine targeting omicron resulted in a 13.5-times increase in neutralizing antibody titers with 30 micrograms and a 19.6-times increase with 60 micrograms. The bivalent vaccine, which targeted omicron and the original coronavirus strain, proved a 9.1- and 10.9-times increase, respectively, at the 30 and 60 microgram levels.
“Based on these data, we believe we have two very strong omicron-adapted candidates that elicit a substantially higher immune response against omicron than we’ve seen to date,” Pfizer CEO Albert Bourla, PhD, said in a June 25 press release.
The research shows a stronger response against omicron’s BA.1 strain compared to “sister variants” BA.4 and BA.5.
The FDA is set to meet June 28 to discuss COVID-19 vaccine research, which will include Pfizer’s data on its updated vaccine.
Other companies, including Moderna and Sanofi-GSK, are aiming to tackle the omicron variant with their own vaccine candidates.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.